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Abstract
Previous studies of biopharmaceutical and biotechnology innovation  ADDIN EN.CITE (Bartholomew, 1997, Mani, 2005, Chaturvedi, 2007) suggest that one of the key determinants of success is the flow of knowledge between actors within the innovation system. The production, transfer and use of biopharmaceutical knowledge is best conceived as occurring in collaborative networks that link firms, academic scientists, medical institutions, venture capitalists, and government agencies ( ADDIN EN.CITE Owen-Smith and Powell 2001a, 2001b, 2004; Powell and Owen-Smith, 1998). In particular, Owen-Smith and Powell (2001a) argue that commercialisation of biotechnology is driven by various factors such as the changing institutional mandates for universities, funding opportunities, and new research technologies. Furthermore, a number of studies have highlighted how “power asymmetries” rooted in the relationships between the key actors affects the development of technologies (Klein & Kleinman 2002; Feenberg1999, Winner 1993). More recently, Vallas and Kleinman, (2007), concluded that the interaction between universities and industry is changing and is now marked by a pattern of “asymmetrical convergence”, This is characterised by the integration of the normative codes and practices of industry into academia, yielding structures of knowledge production that assume novel and contradictory forms (Kleinman and Vallas, 2001). The similar concept of “academic capitalism” has also been discussed in Slaughter ‘s work, referring to the cultivation of entrepreneurialism within the public sector, encompassing grantsmanship, the development of research programs and technology transfer (Slaughter and Rhoades 2004). 

The aim of this study is to analyze the changing dynamic of collaboration between the key actors, including domestic and foreign organisations within the Taiwanese biopharmaceutical innovation systems, and the role that emerging institutions which specifically promoted biopharmaceutical innovation have played during the last decade. Empirically more than 50 semi-structured interviews were then conducted with the key actors involved in knowledge transfer and research collaborations, including academic scientists, company managers, policy makers, government officials, technology transfer officers in a variety of research institutes, as well as the major knowledge brokers in the field. 
A number of findings were identified: 1)“systematic asymmetries of power” existed between the actors in the interactive process of technology development and policy-making. 2) Several leading groups, including clinicians, representatives of VC, and the directors of academia centres, controlled the direction of research, resource allocation and policy-making. 3) These leading groups transplanted concepts of entrepreneurship and several policy initiatives from North America into Taiwanese academia. This has both stimulated and framed academia-industry collaboration and knowledge transfer. 4) In this context the norms of industry have become dominant, reinforcing a pattern of “asymmetrical convergence” between academic and commercial research. 5) The changing dynamic of institutions and social norms have been transformed from prohibiting academic involvement with the commercialization process into encouraging publicly funded researchers to collaborate with commercial entities. 

In conclusion, the findings highlight the way in which the changing of role of institutions driven by the dynamic of technology policy, the asymmetries of power between actors, and the shifting boundaries between the public and private sectors are pushing research collaboration to become more profit-oriented with greater emphasis on market potential and the clinical development of new products.













